| Literature DB >> 27517806 |
Navaneethakrishnan Polachi1, Guirong Bai1, Tingyang Li2, Yang Chu1, Xiangyang Wang1, Shuming Li1, Ning Gu3, Jiang Wu3, Wei Li4, Yanjun Zhang5, Shuiping Zhou1, He Sun1, Changxiao Liu6.
Abstract
Silibinin, a natural flavanone, derived from the milk thistle plant (Silybum marianum), was illustrated for several medicinal uses such as liver-protective, anti-oxidant, anti-cancer, anti-inflammation and many other. However, silibinin has poor absorbance and bioavailability due to low water solubility, thereby limiting its clinical applications and therapeutic efficiency. To overcome this problem, the combination of silibinin with phosphatidylcholine (PC) as a formulation was used to enhance the solubility and bioavailability. The results indicated that silibinin-PC taken orally markedly enhanced bioavailability and therapeutic efficiency. In addition, a deeper understanding of the signaling pathways modulated by silibinin is important to realize its potential in developing targeted therapies against liver disorders and cancer. Silibinin has been shown to inhibit many cell signaling pathways in preclinical models, demonstrating promising effects against liver disorders and cancer through in vitro and in vivo studies. This review summarizes the pharmacokinetic properties, bioavailability, safety data, clinical activities and modulatory effects of silibinin in different cell signaling pathways against liver disorders and cancer.Entities:
Keywords: Apoptosis; Cancer; Hepatoprotective; Milk thistle; Phosphatidyl choline; Silibinin
Mesh:
Substances:
Year: 2016 PMID: 27517806 DOI: 10.1016/j.ejmech.2016.07.070
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514